The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine
Open accessAbstract
Carcinogenesis is an evolutionary process that establishes the 'hallmarks of cancer' by natural selection of cell clones that have acquired advantageous heritable characteristics. Evolutionary adaptation has also been proposed as a mechanism that promotes drug resistance during systemic cancer therapy. This review summarises the evidence for the evolution of resistance to cytotoxic and targeted anti-cancer drugs according to Darwinian models and highlights the roles of genomic instability and high intra-tumour genetic heterogeneity as major accelerators of this evolutionary process. Clinical implications and strategies that may prevent the evolution of resistance or target the origins of genetic heterogeneity are discussed. New technologies to measure intra-tumour heterogeneity and translational research on serial biopsies of cancer lesions during and after therapeutic intervention are identified as key areas to further the understanding of determinants and mechanisms of the evolution of drug resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486 · cited 1×
“The EGF receptor tyrosine kinase inhibitor (TKI) gefitinib has high activity in patients with non-small cell lung cancers that harbour activating somatic mutations of the EGF receptor (Lynch et al, 2004).”
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Genetic instabilities in human cancers
Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1998) · Nature · doi:10.1038/25292 · Cited by 4,168 · cited 2×
“Regardless of whether genomic instability is a necessity for carcinogenesis, it has been identified in many advanced tumours and leads to increased genetic intra-tumour heterogeneity (Lengauer et al, 1998).”
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Cancer as an evolutionary and ecological process
Merlo, L. M. F., Pepper, J. W., Reid, B. J., & Maley, C. C. (2006) · Nature Reviews Cancer · doi:10.1038/nrc2013 · Cited by 1,699
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C. V., Inserra, E., Diederichs, S., Iafrate, A. J., Bell, D. W., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800668 · Cited by 1,617
Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,612
Tumor heterogeneity: Causes and consequences
Marusyk, A., & Polyak, K. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.11.002 · Cited by 1,602
(1991) · PubMed · Cited by 1,305
Carter, S. L., Eklund, A. C., Kohane, I. S., Harris, L. N., & Szallasi, Z. (2006) · Nature Genetics · doi:10.1038/ng1861 · Cited by 1,193
Resistance to therapy caused by intragenic deletion in BRCA2
Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011 · cited 1×
“Secondary mutations of the mutant BRCA2 gene, which restore BRCA2 function and lead to PARP inhibitor resistance have been identified in BRCA2-defective cell lines after they acquired resistance to these drugs (Edwards et al, 2008).”
Gatenby, R. A., Silva, A. S., Gillies, R. J., & Frieden, B. R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3658 · Cited by 846
Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia
Mullighan, C. G., Phillips, L. A., Su, X., Ma, J., Miller, C. B., Shurtleff, S. A., & Downing, J. R. (2008) · Science · doi:10.1126/science.1164266 · Cited by 806
Aneuploidy Acts Both Oncogenically and as a Tumor Suppressor
Weaver, B. A. A., Silk, A. D., Montagna, C., Verdier-Pinard, P., & Cleveland, D. W. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.003 · Cited by 729
FIALKOW, P. (1976) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(76)90003-2 · Cited by 647
Kosaka, T., Yatabe, Y., Endoh, H., Yoshida, K., Hida, T., Tsuboi, M., Tada, H., Kuwano, H., & Mitsudomi, T. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0714 · Cited by 589
Roche-Lestienne, C., Soenen-Cornu, V., Grardel-Duflos, N., Laı̈, J.-L., Philippe, N., Facon, T., Fenaux, P., & Preudhomme, C. (2002) · Blood · doi:10.1182/blood.v100.3.1014 · Cited by 515
The genetic origin of drug resistance in neoplasms: implications for systemic therapy.
Goldie, J. H., & Coldman, A. J. (1984) · PubMed · Cited by 511
Tomlinson, I. P. M., Novelli, M. R., & Bodmer, W. F. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14800 · Cited by 458
Inukai, M., Toyooka, S., Ito, S., Asano, H., Ichihara, S., Soh, J., Suehisa, H., Ouchida, M., Aoe, K., Aoe, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1951 · Cited by 452
Hunter, C., Smith, R., Cahill, D. P., Stephens, P., Stevens, C., Teague, J., Greenman, C., Edkins, S., Bignell, G., Davies, H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0127 · Cited by 434
Yip, S., Miao, J., Cahill, D. P., Iafrate, A. J., Aldape, K., Nutt, C. L., & Louis, D. N. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3012 · Cited by 400
Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing
Campbell, P. J., Pleasance, E. D., Stephens, P. J., Dicks, E., Rance, R., Goodhead, I., Follows, G. A., Green, A. R., Futreal, P. A., & Stratton, M. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801523105 · Cited by 365
Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia
Mullighan, C. G., Phillips, L. A., Su, X., Ma, J., Miller, C. B., & Downing, J. R. (2008) · Blood · doi:10.1182/blood.v112.11.429.429 · Cited by 309
THE GENETICS OF BREAST CANCER SUSCEPTIBILITY
Rahman, N., & Stratton, M. R. (1998) · Annual Review of Genetics · doi:10.1146/annurev.genet.32.1.95 · Cited by 295
Chromosomal instability determines taxane response
Swanton, C., Nicke, B., Schuett, M., Eklund, A. C., Ng, C., Li, Q., Hardcastle, T., Lee, A., Roy, R., East, P., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811835106 · Cited by 287
Self-citationMad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal
Sotillo, R., Schvartzman, J.-M., Socci, N. D., & Benezra, R. (2010) · Nature · doi:10.1038/nature08803 · Cited by 273
Fialkow, P. J. (1979) · Annual Review of Medicine · doi:10.1146/annurev.me.30.020179.001031 · Cited by 189
Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia
Williams, R. T., den Besten, W., & Sherr, C. J. (2007) · Genes & Development · doi:10.1101/gad.1588607 · Cited by 180
Refractoriness to Antivascular Endothelial Growth Factor Treatment: Role of Myeloid Cells
Shojaei, F., & Ferrara, N. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0925 · Cited by 171
Duesberg, P., Stindl, R., & Hehlmann, R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.26.14295 · Cited by 165
Circumventing Resistance to Kinase-Inhibitor Therapy
Druker, B. J. (2006) · New England Journal of Medicine · doi:10.1056/nejme068073 · Cited by 149
Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants
Skaggs, B. J., Gorre, M. E., Ryvkin, A., Burgess, M. R., Xie, Y., Han, Y., Komisopoulou, E., Brown, L. M., Loo, J. A., Landaw, E. M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609239103 · Cited by 142
Cancer: the evolutionary legacy
Leonard, R. C. F. (2000) · Choice Reviews Online · doi:10.5860/choice.38-1549 · Cited by 122
Greaves, M. F. (2000) · doi:10.1093/oso/9780192628350.001.0001 · Cited by 92
Cancer Genome Sequencing—An Interim Analysis
Fox, E., Salk, J. J., & Loeb, L. A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1231 · Cited by 76
Evolutionary dynamics of mutator phenotypes in cancer: implications for chemotherapy.
Komarova, N. L., & Wodarz, D. (2003) · PubMed · Cited by 66
Random mutations, selected mutations: A PIN opens the door to new genetic landscapes
Klein, C. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609000103 · Cited by 29
Cited by
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Self-citationDecoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach
Aerts, H. J. W. L., Velazquez, E. R., Leijenaar, R. T. H., Parmar, C., Grossmann, P., Carvalho, S., Bussink, J., Monshouwer, R., Haibe-Kains, B., Rietveld, D., et al. (2014) · Nature Communications · doi:10.1038/ncomms5006 · Cited by 5,132
“This heterogeneity is a clear barrier to the goal of personalized therapy based on molecular biopsy-based assays, as the identified mutations and gene-expression does not always represent the entire population of tumour cells 17,18 .”
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia
Landau, D. A., Carter, S. L., Stojanov, P., McKenna, A., Stevenson, K., Lawrence, M. S., Sougnez, C., Stewart, C., Sivachenko, A., Wang, L., et al. (2013) · Cell · doi:10.1016/j.cell.2013.01.019 · Cited by 1,379
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma
Johnson, B. E., Mazor, T., Hong, C., Barnes, M., Aihara, K., McLean, C. Y., Fouse, S. D., Yamamoto, S., Ueda, H., Tatsuno, K., et al. (2014) · Science · doi:10.1126/science.1239947 · Cited by 1,362
Gerlinger, M., Horswell, S., Larkin, J., Rowan, A. J., Salm, M. P., Varela, I., Fisher, R., McGranahan, N., Matthews, N., Santos, C. R., et al. (2014) · Nature Genetics · doi:10.1038/ng.2891 · Cited by 1,208
Self-citation
Metadata
- Authors
- Gerlinger, M., & Swanton, C.
- Venue
- British Journal of Cancer
- Published
- 2010-09-28
- Volume
- 103
- Issue
- 8
- Pages
- 1139-1143
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2125792957
- Cited by
- 421
- References
- 40
- FWCI
- 7.68
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.